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Abstract
Background
Sleeping sickness (human African trypanosomiasis [HAT]) is a neglected tropical disease
with limited treatment options that currently require parenteral administration. In previous
studies, orally administered pafuramidine was well tolerated in healthy patients (for up to 21
days) and stage 1 HAT patients (for up to 10 days), and demonstrated efficacy comparable
to pentamidine.
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Methods
This was a Phase 3, multi-center, randomized, open-label, parallel-group, active control
study where 273 male and female patients with first stage Trypanosoma brucei gambiense
HAT were treated at six sites: one trypanosomiasis reference center in Angola, one hospital
in South Sudan, and four hospitals in the Democratic Republic of the Congo between
August 2005 and September 2009 to support the registration of pafuramidine for treatment
of first stage HAT in collaboration with the United States Food and Drug Administration.
Patients were treated with either 100 mg of pafuramidine orally twice a day for 10 days or 4
mg/kg pentamidine intramuscularly once daily for 7 days to assess the efficacy and safety
of pafuramidine versus pentamidine. Pregnant and lactating women as well as adolescents
were included.
The primary efficacy endpoint was the combined rate of clinical and parasitological cure
at 12 months. The primary safety outcome was the frequency and severity of adverse
events. The study was registered on the International Clinical Trials Registry Platform at
www.clinicaltrials.gov with the number ISRCTN85534673.
Findings/Conclusions
The overall cure rate at 12 months was 89% in the pafuramidine group and 95% in the pent-
amidine group; pafuramidine was non-inferior to pentamidine as the upper bound of the
95% confidence interval did not exceed 15%. The safety profile of pafuramidine was supe-
rior to pentamidine; however, 3 patients in the pafuramidine group had glomerulonephritis
or nephropathy approximately 8 weeks post-treatment. Two of these events were judged as
possibly related to pafuramidine. Despite good tolerability observed in preceding studies,
the development program for pafuramidine was discontinued due to delayed post-treatment
toxicity.
Author Summary
Sleeping sickness, or human African trypanosomiasis (HAT), is a neglected tropical dis-
ease. Because only 2 treatment options are available to treat persons with stage 1 disease,
and both require parenteral administration, oral drugs would be of great benefit to the
affected population. In this Phase 3, multi-center, randomized, open-label, parallel-group
study, we compared oral pafuramidine with intramuscular pentamidine in persons in sub-
Sahara Africa with first stage HAT. At 12 months, the overall cure rates (combined clinical
and parasitological cure) were similar: 89% in the pafuramidine group and 95% in the
pentamidine group. At 24 months, the cure rates continued to be high: 84% and 89%,
respectively. Pafuramidine’s safety profile was superior to the comparator drug, and it was
consistent with the overall safety profile seen in previous Phase 2 studies. Upon further
analysis, however, a renal safety issue was identified as being possibly related to pafurami-
dine and further clinical development was halted. Nevertheless, the clinical studies con-
ducted in the pafuramidine development program provide a model for future studies in
rural Africa.
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Introduction
Sleeping sickness (human African trypanosomiasis [HAT]) is a neglected tropical disease with
limited treatment options that currently require parenteral administration. Trypanosoma bru-
cei (T.b.) gambiense is found in 24 countries in west and central Africa and currently accounts
for over 98% of reported cases [1]. Despite the long history of the disease (first cases reported
in 1373/1374), the drugs available to treat it are toxic, difficult to administer, and stage-specific
[2].
First stage symptoms entail bouts of fever, headaches, joint pains, and itching, and a person
can be infected for months or even years without major signs or symptoms of the disease.
When more evident symptoms emerge, the patient is often already in an advanced disease
stage where the central nervous system is affected (second stage). The majority of current HAT
research is focused on stage 2 of the disease, which requires drugs that can cross the blood-
brain barrier. Drugs for stage 2 HAT are either too toxic (melarsoprol) or have too complex a
regimen (nifurtimox-eflornithine combination treatment) for use against the first stage of the
disease.
Only two drugs are approved for treatment of stage 1 HAT: pentamidine (only for T.b. gam-
biense) and suramin (only for T.b. rhodesiense), which are both administered parenterally. Sur-
amin, synthesized as a dye in 1916 [3], has been used for the treatment of sleeping sickness
since 1922 [4] [5], but it can cause undesirable effects in the urinary tract and allergic reactions
[1]. Pentamidine, introduced in 1937, was developed as an analog of synthalin, a hypoglycemic
agent with anti-trypanosomal activity [6] [7]. Pentamidine is administered by the intramuscu-
lar route and has a reported treatment failure rate after a course of five injections of approxi-
mately 7% [8] [9] [10]. Though this efficacy profile is encouraging, treatment with
pentamidine has limitations. It requires injection, which hampers its use in rural treatment
facilities, and though adverse reactions are usually reversible and its most serious long-term
consequence, diabetes, is rare, the treatment is accompanied by a high frequency of adverse
events, including hypotension, nephrotoxic effects, leukopenia, and hypo- and hyperglycemia
[11] [12].
There is no vaccine for T.b. gambienseHAT and there is a great need for new safe and effica-
cious drugs that would be easy to use in rural health centers and affordable. In 2000, the prom-
ising orally administered pro-drug pafuramidine was chosen for clinical development by the
Consortium for Parasitic Drug Development, which was founded in 1999 to foster the develop-
ment of compounds with antiprotozoal activity [13]. Pafuramidine is the dimethoxime pro-
drug of furamidine (which has demonstrated excellent efficacy in vitro against T.b.
rhodesiense) [14]. Pafuramidine was shown to be effective in vivo in the acute model (first stage
disease) in mice [15] [16] and in monkeys (green vervet monkey [17] and rhesus monkey
[18]). Preclinical evaluation in vitro as well as animal testing indicated no major safety
concerns.
In 2000, pafuramidine was further evaluated in Phase 1 studies in healthy patients after sin-
gle and multiple dosing (up to 21 days) and was well tolerated [19]. The subsequent Phase 2
studies (conducted from 2001 to 2007) in patients with stage 1 sleeping sickness supported this
finding [20]. Efficacy after 5 days of treatment was limited; therefore, to attain efficacy compa-
rable to that of pentamidine, the treatment duration was prolonged to 10 days. The pharmaco-
kinetic properties of pafuramidine (in particular, the lack of proportional conversion of DB289
to DB75 at therapeutic doses) precluded using a higher dose to improve efficacy [19] [20] [21]
[22].
This single, confirmatory, pivotal Phase 3 study was developed to support the registration of
pafuramidine for treatment of stage 1 HAT under a Special Protocol Assessment in
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collaboration with the United States (US) Food and Drug Administration (FDA). The primary
objective of the study was to demonstrate the non-inferiority of oral pafuramidine versus intra-
muscular pentamidine for treatment of first stage HAT caused by T.b. gambiense. Since safety
and efficacy of a new drug should, if at all possible, be established in a study population repre-
sentative of the target population, the secondary objective was to include pregnant and lactat-
ing women as well as adolescents in the study. Reproductive studies of pafuramidine in
animals have not indicated any embryo or fetal toxicity or other effects on reproductive func-
tion of adult male and female rats or rabbits. Therefore, it was considered appropriate and was
approved by the US FDA to proceed with studies including pregnant and lactating women.
Methods
Design
This was a multi-center, multi-country, open-label (sponsor-blinded), parallel-group, compar-
ator-controlled, randomized Phase 3 study to compare the efficacy, safety, and tolerability of
pafuramidine and pentamidine in 273 patients with first stage HAT caused by T.b. gambiense.
The study was conducted at six African sites where T.b. gambiense sleeping sickness is endemic:
two trypanosomiasis reference centers (Angola and the Democratic Republic of the Congo
[DRC]) and four hospitals (1 in South Sudan and three in the DRC) from August 2005 (first
patient enrolled) to September 2009 (last patient follow-up completed).
The study was registered on the International Clinical Trials Registry Platform at www.
clinicaltrials.gov with the number ISRCTN85534673. International Protocol #289-C-006.
Ethics statement. This will certify that the Institutional Review Boards (IRBs) at the Uni-
versity of North Carolina at Chapel Hill, administered by the Office of Human Research Ethics,
are organized and operate according to applicable laws and regulations governing research
involving human subjects. These include, when applicable, statutes of the State of North Caro-
lina and regulations of the Food and Drug Administration (21 CFR 50 and 56) and the Depart-
ment of Health and Human Services [45 CFR 46 (the "Common Rule") and 45 CFR 164 (the
Health Insurance Portability and Accountability Act, HIPPAA]. In addition, the IRBs conform,
when applicable, to Good Clinical Practice (GCP) guidelines of the International Conference
of Harmonization (ICH), to the extent these do not contradict DHHS and FDA regulations.
The University of North Carolina at Chapel Hill holds a Federalwide Assurance, FWA 4801,
approved by the federal Office for Human Research Protections (OHRP).
This study was approved by the following independent review boards and independent eth-
ics committees: Ethikkommission beider Basel, Switzerland; the institutional review board of
the University of North Carolina, School of Medicine, US., IRB# 05–2062 (Formerly
05-PATH/LAB-573; the Ethics Committee for Trypanosomiasis Research of the Ministry of
Health of Angola; the Ethics Committee of the Ministry of Health of the DRC; and the Ethics
Committee of the Ministry of Health of the Government of Southern Sudan.
Patients were randomized (1:1) to either 100 mg of pafuramidine orally twice a day (BID)
for 10 days (n = 136) or 4 mg/kg pentamidine intramuscular injection once daily for 7 days
(n = 137).
Changes to Trial Design
There was one protocol amendment that provided detailed microscopy instructions for exam-
ining blood and CSF for the presence of trypanosomes and determining WBC count in CSF.
The amendment also detailed randomization of pregnant and lactating women in a separate
strata, and provided additional clarifications and administrative changes.
Pafuramidine and Pentamidine for Stage 1 Sleeping Sickness
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Study Patients
Male and female patients were eligible to participate if they were12 years of age, weighed
30 kg, had first stage T.b. gambiense infection documented by the presence of trypanosomes
in the blood and/or lymph, and had no evidence of second stage disease (no trypanosomes
detected in the cerebrospinal fluid [CSF] and5 white blood cells [WBCs]/mm3 in CSF).
Patients were also excluded if tested positive for malaria or helminth infections. Patients were
not tested for HIV prior to treatment. Patients were treated at two trypanosomiasis reference
centers (Angola and the DRC) and four hospitals (1 in South Sudan and three in the DRC).
Written informed consent was obtained from each patient. If the patient was a minor or men-
tally impaired, a legal guardian also signed the consent form and if a patient was illiterate, an
impartial witness assisted in the consent process.
Pregnant and lactating female patients as well as adolescents 12 to 15 years could be
enrolled. Adolescents underwent additional safety laboratory testing at the 3-month post-treat-
ment visit. Eligible pregnant and lactating female patients could participate with the under-
standing that additional safety measurements regarding course and outcome of the pregnancy
and/or the health of their infant would be performed.
Patients were excluded if they had a possible or confirmed second stage T.b. gambiense
infection (ie, presence of parasite in the CSF upon microscopic examination or a WBC count
in the CSF of>5 mm3); any active, clinically relevant medical conditions that in the investiga-
tor’s opinion might jeopardize patient safety or interfere with study participation; presented
with a score of less than 9 on the Glasgow Coma Scale; were previously treated for HAT; or dis-
played other conditions that would compromise participation.
Interventions
Screening occurred within 7 weeks prior to dosing with pafuramidine or pentamidine (within
6 weeks prior to the baseline evaluation) using the card agglutination test for trypanosomes
[11] [12] and microscopic examination (thin and/or thick smear) of blood and lymph node
aspirate for trypanosomes either at the trypanosomiasis treatment centers or by mobile diag-
nostic units. All diagnostic tests performed by mobile teams were repeated in the treatment
centers. Lumbar puncture was performed at the treatment centers in all trypanosome-positive
cases detected by any method and the disease stage was determined by microscopic examina-
tion of CSF for trypanosomes and by WBC counts. If the result was negative, a blood sample
was examined (including hematocrit centrifugation [23] and miniature anion exchange centri-
fugation technique [m-AECT] [24]). All patients were tested for malaria, and filaria using thick
and thin blood smears and for diarrhea. If necessary, malaria treatment was given before enrol-
ment; filariasis therapy was administered after study treatment when necessary. Patients were
admitted as in-patients to the clinical site for the full duration of the treatment/observation
period (11 days for pafuramidine or 7 days for pentamidine). Other baseline documentation
included demographics, medical history, signs and symptoms of HAT, and concomitant dis-
ease(s) and medication(s).
Clinical supplies of pafuramidine were provided to the sites in bottles (50 tablets of 100 mg)
labeled to indicate study drug, strength, expiration date, protocol number, and other informa-
tion according to local regulations. Pentamidine was provided locally by the agency (generally
the national HAT control programs) responsible for each center in the form of pentamidine
isethionate for injection in single-dose vials at 200 mg/vial.
For efficacy assessments, patients underwent microscopic examination of blood (thin and/
or thick smear), hematocrit centrifugation of blood [25], microscopic examination of lymph
node aspirate, and microscopic examination of blood after m-AECT concentration at the end
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of treatment and at 3, 6, 12, and 18 months post-treatment [26]. Lumbar puncture was per-
formed for microscopic examination of CSF fluid for WBCs and trypanosomes at baseline and
6, 12, and 18 months post-treatment, and at any other evaluation where relapse was suspected
or trypanosomes were demonstrated in blood or lymph nodes. Additional assessments of clini-
cal efficacy were performed at 24 months post-treatment.
During the treatment and post-treatment period, safety evaluations included vital signs,
physical examination, adverse event monitoring, laboratory tests, electrocardiogram (ECG)
monitoring to the extent possible at each site, and documentation of concomitant medications.
Signs or symptoms of HAT were queried and graded. Laboratory tests assessed clinical chemis-
try (aspartate aminotransferase, alanine aminotransferase, total bilirubin, glucose, and creati-
nine) and hemoglobin. Electrocardiograms were performed at baseline, 1 hour prior to dosing,
and 1 hour after dosing for all patients. An additional ECG was obtained on Day 7 post-treat-
ment for pafuramidine-treated patients.
Outcomes
Clinical response definitions are listed in Table 1. The primary efficacy endpoint was the com-
bined rate of cure and probable cure at the 12-month follow-up in the per-protocol data set.
The overall cure rate was defined as the proportion of treated patients with no clinical signs
and symptoms of HAT, no evidence of trypanosomes in any body fluid examined, and no
treatment with other trypanocidal agents for any reason; in addition,5 WBCs/mm3 in CSF
obtained from a lumbar puncture was required.
Secondary efficacy endpoints were cure, clinical cure, probable relapse, relapse, and death
rates at the end of treatment and all follow-up visits. Parasitological cure, probable relapse,
relapse, and death rates were also assessed at the 12-month test of cure evaluation and at the
24-month evaluation; the clinical cure was considered equivalent to the parasitological cure at
the 24-month evaluation.
Study efficacy parameters and timing of post-treatment evaluations were based on WHO
recommendations for clinical product development for HAT [27]. Although 18 months post-
Table 1. Clinical response definitions.
Category WHO Term Characteristics
Parasitological
cure
Cure Lumbar puncture performed: no evidence for parasitological relapse and 5 WBCs/mm3 in CSF
Clinical cure Probable
cure
No evidence for parasitological relapse in absence of lumbar puncture (no clinical signs; symptoms/signs attributable
to other disease; investigator decides no retreatment necessary)
or No parasitological evidence of relapse with 6–0 WBCs/mm3 in CSF
Action: No retreatment
Probable
relapse
Probable
relapse
No evidence of parasitological relapse and >20 WBCs/mm3 in CSF
or No evidence of parasitological relapse in a patient who refuses lumbar puncture and who presents with clinical
signs of HAT and/or marked deterioration of clinical condition relative to previous evaluations that is unlikely due to
another disease. In addition, in the investigator’s opinion, all other reasons for the patient’s clinical status have been
excluded and rescue treatment is required.
Action: Retreatment
Relapse Relapse Trypanosomes have been detected in any body fluid
Action: Retreatment
Death Death Death of patient during treatment or follow-up; death will be categorized based on likely or definite cause of death as
HAT; adverse event related to treatment of HAT; causes unrelated to HAT and treatment; unknown causes
CSF = cerebrospinal fluid, HAT = human African trypanosomiasis, WBCs = white blood cells, WHO = World Health Organization
doi:10.1371/journal.pntd.0004363.t001
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treatment is recommended to assess clinical cure in HAT control programs due to anticipated
increased drop-out rates from follow-up after 6 to 12 months, the 12-month evaluation was
chosen as the primary endpoint in this study in order to maintain a robust data set for the pri-
mary analysis.
Safety was assessed through the end of treatment evaluation and included adverse events,
laboratory results, vital sign measurements, physical examinations, and use of any concomitant
medications. The term “adverse event” included any of the following events that developed or
increased in severity during the study: 1) any signs or symptoms whether thought to be related
or unrelated to HAT; 2) any clinically significant laboratory abnormality; or 3) any abnormal-
ity detected during physical examination. Adverse events were graded by the investigator
(1 = mild, 2 = moderate, 3 = severe, 4 = intolerable). Adverse events were assessed at every
study visit and were classified according to the terms found in the Medical Dictionary for Regu-
latory Activities (MedDRA).
A serious adverse event was defined as any event that suggested a significant hazard, con-
traindication, side effect, or precaution, it included any event that: 1) is fatal; 2) is life
threatening; 3) is a persistent or significant disability/incapacity; 4) requires or prolongs in-
patient hospitalization; 5) is a congenital anomaly/birth defect; or 6) is an important medi-
cal event, based upon appropriate medical judgment, that may jeopardize the patient or
may require medical or surgical intervention to prevent one of the other outcomes defining
serious.
Changes to Outcomes
There were no changes to any of the outcomes.
Sample Size
A total of 250 patients, 125 patients per treatment group, were originally expected to be treated
in order to include 100 patients per treatment group in the per-protocol. This sample size pro-
vided more than 90% power to demonstrate non-inferiority of pafuramidine to pentamidine
for the primary endpoint, when the study drugs have equivalent probable cure rates of 95% in
the per-protocol analysis. Non-inferiority comparison was conducted with an alpha equal to
0.048 and non-inferiority margin (ie, delta) of 0.15.
Stopping Guidelines and Interim Analysis
The sponsor may have terminated this study prematurely, either in its entirety or at a particular
site, for reasonable cause or safety concerns. The sponsor remained blinded and the data were
provided to the data safety monitoring board (DSMB) for evaluation. Based on these data, the
DSMB made recommendations to the sponsor regarding continuation of the study. The study
could have been stopped if: 1) any new untoward safety issues were identified in the pafurami-
dine treatment group such that pafuramidine was significantly less safe than pentamidine; 2)
the re-estimated sample size exceeded 500 patients to achieve 90% power for the primary effi-
cacy endpoint; or 3) efficacy analysis indicated that pafuramidine was significantly more effec-
tive than pentamidine (p<0.002).
An interim analysis was to be conducted when half of the enrolled patients reached the
12-month post-treatment endpoint, however, this was not done because the pafuramidine
development program was discontinued due to delayed post-treatment toxicity (details are
provided in the Harms section).
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Randomization
Patients were randomly assigned by the local investigators to receive either pafuramidine or
pentamidine in the order in which they were enrolled. Randomization was carried out in blocks
of variable size following a randomization schedule prepared by the sponsor; randomization of
pregnant and lactating women was stratified. Each study site was provided with series of indi-
vidual envelopes each containing a card with the treatment assignment for 1 patient and a con-
trol number. After a patient signed the informed consent and inclusion/exclusion criteria were
confirmed, the investigator opened the next envelope in the randomization list to obtain treat-
ment assignment for that patient and then transferred the control number to the patient’s case
report form.
Blinding
The study was open-label, since pafuramidine is administered orally and pentamidine is
administered intramuscularly. However, the sponsor was blinded to treatment assignments.
Statistical Methods
The primary efficacy analysis, demonstrating the non-inferiority of pafuramidine to pentami-
dine for the combined rate of cure and probable cure, was conducted with an alpha equal to
0.048 and non-inferiority margin (ie, delta) of 0.15. The comparison was made with a 1-sided
97.6% confidence interval (CI) for the treatment difference in parasitological cure rate. The
normal approximation to the binomial distribution with continuity correction was used to con-
struct the CI. The primary data set for efficacy analysis was the per-protocol data set.
The efficacy analysis was carried out for the per-protocol data set (primary analysis), the
intention-to-treat (ITT) data set, and the modified ITT (mITT) data set (supportive analyses).
The per-protocol data set was defined as patients who received a minimum of 7 days of pafura-
midine or five injections of pentamidine and who attended the test of cure assessment at
Month 12 or reached an efficacy endpoint (death, non-response, or relapse) at an earlier time.
Patients without lumbar puncture at Month 12 were included and their outcome was assessed
based on clinical signs and symptoms and parasitological findings from any body fluid
examined.
The mITT data set consisted of all patients who received the minimum amount of random-
ized study drug (7 or 5 days) and for whom an end-of-treatment assessment and at least one
follow-up efficacy assessment were available. Patients who had received at least one dose of
study drug were included in the ITT data set and patients who were lost to follow-up or discon-
tinued from the study for any reason were considered treatment failures in the ITT analysis.
The last observation carried backward was used to account for missing data at an earlier evalu-
ation (in case of cure at a later evaluation). For the mITT analysis, missing data were addressed
according to the last observation carried forward principle.
The secondary efficacy variables were summarized at all time points with point estimates
and 1-sided 97.5% CIs for the difference between treatments.
The safety data set consisted of all patients who received at least one dose of study drug and
had at least one safety evaluation after dosing. Treatment group differences in the proportion
of patients who reported treatment-emergent adverse events for Day 1 through Day 11 were
assessed with Fisher’s exact test.
The number and percentage of patients who reported treatment-emergent adverse events
were summarized for each treatment group at the system organ class, high-level group terms,
and preferred term level. Treatment group differences in the proportion of patients who
reported each high-level group term were assessed with Fisher’s exact test.
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Any clinically significant physical examination changes from baseline were captured as an
adverse event.
Results
Participant Flow
First stage HAT patients rarely present at a hospital or a treatment center. Therefore, intense
screening activities were necessary. Between July 2005 and March 2007, a total of 234,919
patients were screened to find 839 individuals affected with HAT (Fig 1). The exclusion rate
was high (566 of 839 patients, 67.5%); primary reasons were that patients had stage 2 HAT and
did not meet inclusion criteria. A total of 273 patients were randomized: 136 patients received
pafuramidine and 137 received pentamidine; all 273 completed the study. Most of the patients
(91%) were enrolled in the DRC (248 of 273 patients); 5.5% were enrolled in Angola (15 of 273
patients), and 3.7% (10 of 273 patients) were enrolled in South Sudan.
As shown in Fig 1, follow-up attendance at Month 24 was good; only 2 patients in the pafur-
amidine group and 8 patients in the pentamidine group were lost to follow-up.
Baseline Data
As seen in Table 2, baseline demographic characteristics between the two treatment groups
were similar. The median age of patients in both treatment groups was approximately 30 years,
and the majority of patients in both groups were female (70% and 66%, respectively).
Numbers Analyzed and Excluded
As shown in Fig 1, 133 of 136 patients (97.8%) in the pafuramidine group and 129 of 137
patients (94.2%) in the pentamidine group were included in the efficacy analysis. Three
patients in the pafuramidine group and 8 patients in the pentamidine group were excluded
because they were lost to follow-up.
Outcomes and Estimations
As shown in Table 3 at the test of cure evaluation (12 months post-treatment), the combined
rate of cure and probable cure was 89% (118 of 133 patients) in the pafuramidine group and
95% (123 of 129 patients) in the pentamidine group in the per-protocol population.
Pafuramidine was non-inferior to pentamidine as the upper bound of the 95% CI did not
exceed 15%. This finding was supported by the 24-month follow-up data, where cure rates of
84% for the pafuramidine group and 89% for the pentamidine group were maintained
(Table 4). Supportive analysis in the ITT and mITT populations generated similar results.
Table 5 summarizes the secondary efficacy variables for each follow-up visit, including the
cumulative number of cures, probable cures, probable relapses, relapses, and deaths for each
treatment group. There were no deaths in either treatment group during the active study
period, and all patients responded to treatment. Relapses in the pafuramidine treatment group
appeared to be evenly distributed over the whole follow-up period, whereas a trend for late
relapses was observed in the pentamidine treatment group.
The numbers of adolescents and pregnant women (8 and 10, respectively) were too small to
make any definitive conclusions about efficacy in these patients. For lactating women, the over-
all cure rates of pafuramidine and pentamidine at the test of cure evaluation were the same (23
of 26 patients [88.4%] in each group). However, the low number of lactating women also did
not allow for definitive conclusions.
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Harms
No patients prematurely discontinued due to an adverse event during the study.
As shown in Table 6, the most commonly reported adverse events were injection site pain,
pyrexia, hypoglycemia, and hypotension. These events occurred more frequently in the
Fig 1. Pafuramidine (DB289) Phase 3 study CONSORT flowchart.
doi:10.1371/journal.pntd.0004363.g001
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pentamidine group than the pafuramidine group, with the exception of pyrexia, which
occurred more frequently in the pafuramidine group. The incidence of patients with at least
one adverse event overall for Day 1 through Day 11 was statistically significantly less in the
pafuramidine treatment group (82%, 111 of 136) than in the pentamidine group (99%, 135 of
137) (p<0.05). Among high-level group terms, there were statistically significant differences in
favor of the pafuramidine treatment group versus the pentamidine group for hepatobiliary
investigations (7% vs. 77%, respectively); renal and urinary tract investigations and urinalyses
(2% vs. 9%, respectively); glucose metabolism disorders (including diabetes mellitus) (6% vs.
18%, respectively); and decreased nonspecific blood pressure disorders and shock (44% vs.
62%, respectively) (p<0.05 for all).
Table 2. Baseline demographics.
Pafuramidine 100 mg BID (N = 136) n (%) Pentamidine 4 mg/kg QD (N = 137) n (%)
Age (years)
Mean (SD) 33.4 (13.66) 33.7 (14.10)
Median 30 31
Min, max 12, 64 13, 75
n (%) >64 years 0 5 (3.6)
Sex
n (%) male 41 (30.1) 47 (34.3)
n (%) female 95 (69.9) 90 (65.7)
Status
Adolescents 8 (5.9) 8 (5.8)
Pregnant 4 (2.9) 8 (5.8)
Lactating 28 (20.6) 26 (19.0)
Pregnant & lactating 1 (0.7) 1 (0.7)
Weight
Mean (SD) 44.7 (7.90) 45.7 (7.82)
Median 44 46
Min, max 30, 64 30, 69
Height (cm) N = 135 N = 137
Mean (SD) 160.4 (9.41) 160.6 (9.38)
Median 160 160
Min, max 139, 187 138, 185
BID = twice a day, QD = once a day, SD = standard deviation
doi:10.1371/journal.pntd.0004363.t002
Table 3. Combined rate of cure and probable cure at 12 months.
Patient Group Pafuramidine Pentamidine 95% CIa
100 mg BID 4 mg/kg QD
n/N (%) n/N (%)
Per-protocol population 118/133 (88.7) 123/129 (95.3) -0.1, 13.1
ITT population 118/136 (86.8) 123/137 (89.8) -4.6, 10.6
mITT population 121/136 (89.0) 131/137 (95.6) 0.4, 12.9
BID = twice a day, CI = confidence interval, ITT = intent-to-treat population, mITT = modified intent-to-treat population, QD = once a day
a Confidence intervals are based on normal approximation to the binomial for pentamidine–pafuramidine.
doi:10.1371/journal.pntd.0004363.t003
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A statistically significantly greater percentage of pafuramidine patients than pentamidine
patients experienced epidermal and dermal conditions (5% vs. 1%, respectively) (p<0.05).
The majority of the adverse events were mild or moderate in severity and typical for patients
recovering from first stage HAT.
The ECG results from this study were included in a separately published study on cardiac
alterations in HAT [28]. In brief, the mean PQ and QTc intervals did not increase during treat-
ment of first stage disease in either treatment group. The appearance and disappearance of
repolarization changes at the end of treatment were comparable between groups.
A total of 43 patients experienced serious adverse events during the study (including the fol-
low-up period): 19 of 136 patients (14.0%) in the pafuramidine group and 24 of 137 patients
(17.5%) in the pentamidine group. Of these, only 3 patients had serious adverse events while
on treatment: 1 in the pafuramidine group (cellulitis considered probably not related to study
drug) and 2 in the pentamidine group (hypersensitivity considered not related to study drug
and subcutaneous abscess considered probably related to the study drug). All other serious
adverse events occurred during the follow-up period.
Of the 43 patients with serious adverse events, it was initially considered probable that only
one was related to the study drug (subcutaneous abscess in the pentamidine group). Re-evalua-
tion of the relatedness of these events to the study drug was subsequently performed when seri-
ous renal and hepatic post-treatment toxicity was observed in 3 patients in a supportive Phase
1 study of pafuramidine, which was conducted in South Africa (in December 2007), during the
follow-up period of the current Phase 3 study. The Phase 1 study included 175 male and female
volunteers taking oral pafuramidine 100 mg BID for 14 days [19]. Retrospectively, the glomer-
ulonephritis reported for the 2 pafuramidine patients in the current Phase 3 study was consid-
ered to be possibly related to the study drug.
Thirteen patients (6 in the pafuramidine group and 7 in the pentamidine group) died during
the follow-up period. All deaths were considered not related or probably not related to the
study drug. Two deaths in the pafuramidine group were considered to be related to HAT; one
death was considered to be related to relapse of HAT and another was considered to be associ-
ated with treatment of a HAT relapse with melarsoprol.
Safety data for adolescent as well as pregnant and lactating women were similar to the obser-
vations in the general population.
Discussion
Limitations
Although this study was conducted in rural conditions in Angola, South Sudan, and the DRC
with local teams that had limited experience in clinical studies, this study was fully compliant
Table 4. Combined rate of cure and probable cure at 24 months.
Pafuramidine Pentamidine 95% CIa
100 mg BID 4 mg/kg QD
n/N (%) n/N (%)
Per-protocol population 113/135 (83.7) 116/130 (89.2) -2.7, 13.7
ITT population 113/136 (83.1) 116/137 (84.7) -7.1, 10.3
mITT population 114/136 (83.8) 123/137 (89.8) -2.0, 14.0
BID = twice a day, CI = confidence interval, ITT = intent-to-treat population, mITT = modified intent-to-treat population, QD = once a day
a Confidence intervals based on normal approximation to the binomial for pentamidine–pafuramidine
doi:10.1371/journal.pntd.0004363.t004
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with Good Clinical Practice and regulatory standards. In addition, this was the first Phase 3
study of a new drug intended for treatment of sleeping sickness conducted under a US FDA
Investigational New Drug Application that followed contemporary International Conference
on Harmonisation guidance.
Table 5. Secondary efficacy variables at months 3, 6, 12, 18, and 24 (per-protocol dataset).
Pafuramidine Pentamidine
WHO Efficacy Criteria 100 mg BID 4 mg/kg QD
Time Point n/N (%) n/N (%) 95% CIa
Cure
Month 3 2/135 (1.5) 1/137 (0.7) -3.2, 1.7
Month 6 124/135 (91.9) 131/137 (95.6) -2.0, 9.5
Month 12 117/133 (88.0) 122/129 (94.6) -0.2, 13.4
Month 18 99/131 (75.6) 109/129 (84.5) -0.7, 18.6
Month 24 86/135 (63.7) 83/130 (63.8) -11.4, 11.7
Probable cure
Month 3b 131/135 (97.0) 135/137 (98.5) -2.0, 5.0
Month 6b 5/135 (3.7) 3/137 (2.2) -5.5, 2.5
Month 12b 4/133 (3.0) 4/129 (3.1) -4.1, 4.3
Month 18b 16/131 (12.2) 13/129 (10.1) -9.8, 5.5
Month 24c 28/135 (20.7) 34/130 (26.2) -4.8, 15.6
Probable relapse
Month 3 0 0 --
Month 6 2/135 (1.5) 1/137 (0.7) -3.2, 1.7
Month 12 5/133 (3.8) 1/129 (0.8) -6.6, 0.6
Month 18 7/131 (5.3) 1/129 (0.8) -8.7, -0.4
Month 24 11/135 (8.1) 3/130 (2.3) -11.1, -0.6
Relapsed
Month 3 2/135 (1.5) 1/137 (0.7) -3.2, 1.7
Month 6 2/135 (1.5) 1/137 (0.7) -3.2, 1.7
Month 12 3/133 (2.3) 1/129 (0.8) -4.4, 1.5
Month 18 4/131 (3.1) 3/129 (2.3) -4.7, 3.2
Month 24 5/135 (3.7) 3/130 (2.3) -5.5, 2.7
Death
Month 3 0 0 --
Month 6 2/135 (1.5) 1/137 (0.7) -3.2, 1.7
Month 12 4/133 (3.0) 1/129 (0.8) -5.5, 1.0
Month 18 5/131 (3.8) 3/129 (2.3) -5.7, 2.7
Month 24e 5/135 (3.7) 7/130 (5.4) -3.3, 6.7
BID = twice a day, CI = confidence interval, QD = once a day, WHO = World Health Organization
a Confidence intervals based on normal approximation to the binomial.
b Includes cases of “uncertain evolution” [27]
c Includes cases classified as probable cure based on oral information
d One patient in the pentamidine group was classified as a treatment failure at end of treatment and is included in Relapse at Month 3.
e One death was reported in the pafuramidine group subsequent to the last patient visit and is not included in the efficacy endpoints.
doi:10.1371/journal.pntd.0004363.t005
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Table 6. Treatment-emergent adverse events experienced by5% of patients in either treatment group (treatment period).
Pafuramidine 100 mg BID Pentamidine 4 mg/kg QD
SOC (N = 136) (N = 137)
HLGT n (%) n (%)
Preferred Term All Adverse
Events
Treatment-Related Adverse
Eventsa
All Adverse
Events
Treatment-Related Adverse
Eventsa
Total patients with at least 1 adverse eventb 111 (81.6) 54 (39.7) 135 (98.5) 127 (92.7)
Gastrointestinal disorders 21 (15.4) 10 (7.3) 23 (16.8) 12 (8.8)
Gastrointestinal signs and symptoms 18 (13.2) 9 (6.6) 19 (13.9) 12 (8.8)
Abdominal pain 7 (5.1) 1 (0.7) 4 (2.9) 2 (1.5)
Nausea 4 (2.9) 2 (1.5) 11 (8.0) 9 (6.6)
General disorders and administration site
conditions
46 (33.8) 10 (7.4) 61 (44.5) 41 (29.9)
Administration site reactions 0 0 35 (25.5) 35 (25.5)
Injection site pain 0 0 33 (24.1) 33 (24.1)
Body temperature conditions 43 (31.6) 8 (5.9) 33 (24.1) 10 (7.3)
Pyrexia 42 (30.9) 8 (5.9) 31 (22.6) 10 (7.3)
Investigations 33 (24.3) 10 (7.4) 111 (81.0) 108 (78.8)
Haematology investigations (incl blood groups) 17 (12.5) 5 (3.7) 11 (8.0) 6 (4.4)
Haemoglobin decreased 7 (5.1) 2 (1.5) 6 (4.4) 3 (2.2)
Haemoglobin increased 10 (7.4) 3 (2.2) 5 (3.6) 3 (2.2)
Hepatobiliary investigationsb 10 (7.4) 4 (2.9) 106 (77.4) 105 (76.6)
Alanine aminotransferase increased 2 (1.5) 2 (1.5) 72 (52.6) 71 (51.8)
Aspartate aminotransferase increased 7 (5.1) 4 (2.9) 104 (75.9) 103 (75.2)
Metabolic, nutritional and blood gas
investigations
9 (6.6) 3 (2.2) 13 (9.5) 10 (7.3)
Blood glucose decreased 5 (3.7) 2 (1.5) 12 (8.8) 10 (7.3)
Renal and urinary tract investigations and
urinalysesb
3 (2.2) 0 12 (8.8) 6 (4.4)
Blood creatinine increased 3 (2.2) 0 11 (8.0) 5 (3.6)
Metabolism and nutrition disorders 11 (8.1) 1 (0.7) 30 (21.9) 24 (17.5)
Glucose metabolism disorders (including
diabetes mellitus)b
8 (5.9) 0 25 (18.2) 21 (15.3)
Hypoglycaemia 8 (5.9) 0 25 (18.2) 21 (15.3)
Nervous system disorders 24 (17.6) 8 (5.9) 26 (19.0) 19 (13.9)
Headaches 19 (14.0) 5 (3.7) 13 (9.5) 4 (2.9)
Headache 19 (14.0) 5 (3.7) 13 (9.5) 4 (2.9)
Neurological disorders NEC 9 (6.6) 4 (2.9) 16 (11.7) 15 (10.9)
Dizziness 9 (6.6) 4 (2.9) 6 (4.4) 5 (3.6)
Dysgeusia 0 0 11 (8.0) 11 (8.0)
Skin and subcutaneous tissue disorders 7 (5.1) 2 (1.5) 1 (0.7) 0
Epidermal and dermal conditions2 7 (5.1) 2 (1.5) 1 (0.7) 0
Vascular disorders 64 (47.1) 29 (21.3) 86 (62.8) 79 (57.7)
Decreased and nonspecific blood pressure
disorders and shock2
60 (44.1) 28 (20.6) 85 (62.0) 78 (56.9)
Hypotension 60 (44.1) 28 (20.6) 85 (62.0) 78 (56.9)
BID = twice a day, HLGT = high-level group terms, NEC = not elsewhere classified, QD = once a day, SOC = system organ class
a Considered at least possibly related to study drug by the Investigator.
b Statistically significant (p<0.05) difference between treatment groups for overall incidence based on Fisher’s exact test.
doi:10.1371/journal.pntd.0004363.t006
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Interpretation
The results demonstrate the efficacy of pafuramidine in the treatment of first stage HAT, with
an overall cure rate that was statistically non-inferior to that observed for pentamidine (89%
vs. 95%, respectively) at 12 months post-treatment. The results obtained in the per-protocol set
were confirmed in the ITT and mITT analysis populations, which included missing follow-up
visits and patients lost to follow-up. The Month 24 results in all populations corroborate the
12-month results and demonstrate the robustness of the primary efficacy analysis.
Compared with patients who received pentamidine, pafuramidine-treated patients (total
population including the subpopulations of adolescents and pregnant and lactating women)
had lower rates of treatment-related adverse events (93% vs. 40%, respectively) and lower rates
of adverse events related to hepatic, renal, and metabolic toxicity. An ECG analysis revealed no
cardiotoxicity for either drug [28]. These data are consistent with the good tolerability observed
for pafuramidine in the previous Phase 2 studies [20].
This study was also designed to evaluate efficacy and safety of pafuramidine and pentami-
dine in subpopulations that are particularly vulnerable to the long-term socioeconomic bur-
dens associated with HAT, mainly pregnant and lactating women. However, the number of
participating pregnant and lactating women was too low for a thorough separate analysis. The
low number may be a result of social pressures and fear of treatment, which could be a detri-
ment to seeking HAT treatment and going to a hospital. Low fertility and amenorrhea, which
are often associated with HAT, may also have contributed [29]. From the limited number of
relevant patients, there was no evidence for reduced efficacy or additional safety issues relating
to pafuramidine compared with those observed in the overall study population. Numeric cure
rates were similar and no specific safety issues were identified.
The initial safety profile observed for pafuramidine in this study was consistent with the
results of preceding studies in the pafuramidine clinical development program [19] [20]. How-
ever, 3 patients in the pafuramidine group exhibited glomerulonephritis or nephropathy
approximately 8 weeks post-treatment. On further examination, these events appeared to be
similar to events that occurred in the previously mentioned supportive South African Phase 1
safety study. After re-evaluation, 2 of the 3 patients were considered to have events that were
possibly related to pafuramidine by the principal investigator.
It should be noted that the analysis of safety data, particularly of the serious adverse events
that occurred in the HAT study reported here, did not reveal any apparent negative long-term
effects of pafuramidine. The patients who experienced renal toxicity recovered without
sequelae, and the additional safety data obtained during the follow-up revealed no differences
in abnormal biochemistry values between pafuramidine and pentamidine groups.
Eventually, clinical development of pafuramidine was discontinued in early 2008, since the
renal toxicity observed in the additional Phase 1 study was considered to be an unacceptable
risk. Preliminary evidence of the involvement of the kidney injury molecule (KIM-1) was only
very recently provided through the use of a mouse diversity panel [30].
Generalizability
From the perspective of study design, it is noteworthy that the 12-month endpoint for efficacy
effectively predicted the clinical outcomes determined at the 24-month evaluation. Thus, 12
months is a meaningful endpoint for a sleeping sickness study with adequately performed fol-
low-up. The infrastructure and technical expertise developed during the Phase 2 development
program for pafuramidine were effectively leveraged to guide the screening, enrolment, and
oversight of the larger study population included in this Phase 3 registration study, and eventu-
ally led to a unique and comprehensive data set. The successful conduct of the study was
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evidenced by the retention of 97% (265 of 273 patients) of the randomized patients at the
24-month (end-of-study) evaluation. Finally, the lessons learned from the Phase 2 develop-
ment program were also helpful in ensuring that the Phase 3 study complied with Good Clini-
cal Practice and regulatory standards required for a registration study [20].
The repeated success of clinical study conduct throughout the pafuramidine development
program provides a model for future studies in rural Africa and will undoubtedly contribute to
continued improvement of HAT control in sub-Saharan Africa.
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